¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-19
±³À°ÀÏÀÚ : 2019-10-19
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ Art ¿Ü  
±³À°ÁÖÁ¦ : KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ)
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í »çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ-100000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-70000ÇöÀåµî·Ï: ±³¼ö ¹× °³¿øÀÇ-120000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-90000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-19 Art 08:40~09:00 Role of Strain Echocardiography  Á¶±¸¿µ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-19 Art 09:00~09:20 Role CMR  ÃÖ¿¬Çö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-19 Art 09:20~09:40 Role of Cardiac CT with FFR  ±è¿µÇÐ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-19 Art 09:40~10:00 Role of Nuclear Imaing  °­¿øÁØ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 10-19 Art 10:00~10:10 Discussion  () 
È޽Ġ10-19  10:10~10:20 Break  () 
±³À°½Ã°£ 10-19 Calla 10:20~10:40 Role of Vascular Smooth Cell in the Inflammaging of the Artery  Sung Ha Park(Yonsei Univ. Korea) 
±³À°½Ã°£ 10-19 Calla 10:40~11:00 Molecular Imaging for Vascular Inflammation and Atherosclerosis  Jonathan R. Lindner(Oregon Health & Science Univ. USA) 
±³À°½Ã°£ 10-19 Calla 11:00~11:20 Vascular Calcification: Pathogenesis and Clinical Implications  Hae-Young Lee(Seoul National Univ. Korea) 
±³À°½Ã°£ 10-19 Calla 11:20~11:40 Assessment of Capillary Function in Diabetes and Metabolic Syndrome  Jonathan R. Lindner(Oregon Health & Science Univ. USA) 
Åä·Ð 10-19 Calla 11:40~11:50 Discussion  () 
È޽Ġ10-19  11:50~12:00 Break  () 
±³À°½Ã°£ 10-19 Cosmos 12:00~12:20 Optimal Anti-Hypertensives in CardioMetabolic Diseases with Hypertension  ¹Ú»ó¹Î(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-19 Cosmos 12:20~12:40 New Paradigm of Combination Therapy for Uncontrolled Hypertensive Patients  ÀÌÁÖÈñ(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 10-19 Abstract/Case zone & Moderated Poster zone 12:40~14:00 Case Presentation & Moderated Poster  ´Ù°­»ç(´Ù¼Ò¼Ó) 
±³À°½Ã°£ 10-19 Walker 2 14:00~14:20 Best Coronary Revascularization Strategy in Diabetic Patients  ¹Ú´ö¿ì(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-19 Walker 2 14:20~14:40 Secondary Prevention for Coronary Artery Disease in Diabetic Patients  È«¼øÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10-19 Walker 2 14:40~15:00 From Evidence to Practice: SGLT2 Inhibitors for CV Risk Reduction in Diabetes  ÀÓ¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-19 Walker 2 15:00~15:20 From Evidence to Practice: GLP-1 analogues for CV Risk Reduction in Diabetes  ±èº´ÁØ(°¡ÃµÀÇ´ë) 
Åä·Ð 10-19 Walker 2 15:20~15:30 Discussion  () 
È޽Ġ10-19  15:30~15:40 Break  () 
±³À°½Ã°£ 10-19 Theatre 15:40~15:55 Antithrombotic Therapy in Patients with AF Undergoing PCI: Dual or Triple Therapy?  ¹Ú±ÙÈ£(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 15:55~16:10 Antithrombotic Strategy in AF with Stable CAD and PAD  Á¤¿µÈÆ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 16:10~16:25 Antithrombotic Therapy in Korean Patients with AF and CAD: Where Are We Now?  À̼ҷÉ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 16:25~16:40 Periprocedual Management in AF Patients with NOACs: PCI and RFCA  À¯ÈñÅÂ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-19 Theatre 16:40~16:55 Left Atrial Appendage Occlusion in AF Patient with CAD: Which Patients Would Undergo?  ÀÓÈ«ÀÇ(ÇѸ²ÀÇ´ë) 
Åä·Ð 10-19 Theatre 16:55~17:10 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï¼º¸ðº´¿ø ´ëÇÑ¿Ü°úÀ§³»½Ã°æ¿¬±¸È¸ 2019³â ÇϹݱ⠼ú±â ¿öÅ©¼ó ¹× ¿¬¼ö°­Á : 2019-10-19
´ÙÀ½±Û ¼­¿ï¼º¸ðº´¿ø 2019 ´ëÇѼҾÆû¼Ò³â°úÀÇ»çȸ ¼­¿ïÁöȸ ¿öÅ©¼¥ : 2019-10-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
390 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø 2018³â ¾ÆÁÖ´ëÇб³ ¸¶ÃëÅëÁõÀÇÇаú Ãß°è Çмú´ëȸ : 2018-09-01 0 1,244 2018-08-15
389 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7Â÷ International Congress on Lipid Metabolism & Atherosclerosis (ICoLA 2018) : 2018-09-01 0 578 2018-08-15
388 °æ³² â¿ø°æ»ó´ëÇб³º´¿ø 2018³â Áߺΰ泲 ¿¬¼ö±³À° : 2018-09-01 0 930 2018-08-15
387 °­¿ø Á¦19ȸ ´ëÇÑ Ã´Ãß¿Ü°úÇÐȸ ôÃßÅëÁõ¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2018-09-01 0 866 2018-08-15
386 ºÎ»ê Á¦15ȸºÎ¿ï°æÇǺΰúÀÇ»çȸÇмú´ëȸ : 2018-09-01 0 1,079 2018-08-15
385 ¼­¿ï 2018 ¼­¿ï¾Æ»êº´¿ø À̺ñÀÎÈÄ°ú Ãß°è ÀÓ»ó ¿öÅ©¼¥ : 2018-09-01 0 767 2018-08-15
384 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ Á¤Çü¿Ü°úÁúȯ, ¼Õ»ó, Ä¡·á : 2018-09-01 0 1,472 2018-08-15
383 ¼­¿ï Preterm Birth International Collaborative Australasian(´ëÇÑ»êºÎÀΰúÇÐȸ&¼¼°èÁ¶»êÇÐȸ °øµ¿ÁÖ°ü) : 2018-08-31 0 1,136 2018-08-15
382 ¼­¿ï Çѱ¹Á÷¹«½ºÆ®·¹½ºÇÐȸ 2018³â ÇÏ°èÇмú´ëȸ : 2018-08-31 0 560 2018-08-15
381 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7Â÷ International Congress on Lipid Metabolism & Atherosclerosis (ICoLA 2018) : 2018-08-31 0 600 2018-08-15
380 ºÎ»ê ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ºÎ»êÁöºÎÇÐȸ 8¿ù ¿ù·ÊÁý´ãȸ : 2018-08-30 0 1,256 2018-08-15
379 °­¿ø ¿øÁÖ ¼¼ºê¶õ½º ±âµ¶º´¿ø ±âÃʾȰúÁúȯ / CÇü °£¿° : 2018-08-29 0 2,246 2018-08-15
378 ¼­¿ï ´ëÇѼҾư¨¿°ÇÐȸ Á¦154Â÷ ¿ù·Ê¿¬¼ö°­ÁÂ(°¨¿°°ü¸® ¿¬¼ö±³À°) : 2018-08-28 0 630 2018-08-15
377 ¼­¿ï Á¦12ȸ ÁöµµÀü¹®ÀÇ Àü¹®ÇÐȸ(°¡Á¤ÀÇÇÐȸ) ±³À° : 2018-08-25 0 885 2018-08-15
376 ¼­¿ï Á¦13Â÷ ´ëÇѽŰæ¿Ü°úÇÐȸ ¼­¿ï°æÀÎ(°­¿ø-Á¦ÁÖ)Áöȸ : 2018-08-25 0 771 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷